Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial

DOI record: { "DOI": "10.3390/jcm12010142", "ISSN": [ "2077-0383" ], "URL": "http://dx.doi.org/10.3390/jcm12010142", "abstract": "<jats:p>A 28-day randomized open-label multicenter study was conducted to assess the efficacy of bromhexine plus standard of care (SOC) (n = 98) vs. SOC alone (n = 93) in 191 outpatients with mild-to-moderate COVID-19 in the primary health care setting. Bromhexine three daily doses of 10 mL (48 mg/day) were administered for seven days. The primary efficacy endpoint was the reduction of viral load estimated as the cycle thresholds (Ct) to detect ORF1ab, N Protein, and S Protein genes by RT-qPCR in saliva samples on day 4 as compared with baseline. Ct values of the three genes increased from baseline throughout days 4 to 14 (p &lt; 0.001) but significant differences between the study groups were not found. Differences in the percentages of patients with low, medium, and high viral loads at 4, 7, and 14 days were not found either. In summary, treatment with bromhexine plus SCO was associated with a viral load reduction of ORF1ab, N Protein, and S Protein genes at day 4, which was not significantly different than similar viral load reductions observed with SOC alone. The present findings do not seem to favor the use of bromhexine as an antiviral in patients with COVID-19.</jats:p>", "alternative-id": [ "jcm12010142" ], "author": [ { "affiliation": [], "family": "Vila Méndez", "given": "María Luz", "sequence": "first" }, { "affiliation": [], "family": "Antón Sanz", "given": "Carmen", "sequence": "additional" }, { "affiliation": [], "family": "Cárdenas García", "given": "Alicia del Rocío", "sequence": "additional" }, { "affiliation": [], "family": "Bravo Malo", "given": "Amparo", "sequence": "additional" }, { "affiliation": [], "family": "Torres Martínez", "given": "Francisco Javier", "sequence": "additional" }, { "affiliation": [], "family": "Martín Moros", "given": "José María", "sequence": "additional" }, { "affiliation": [], "family": "Real Torrijos", "given": "María", "sequence": "additional" }, { "affiliation": [], "family": "Vendrell Covisa", "given": "José Francisco Javier", "sequence": "additional" }, { "affiliation": [], "family": "Guzmán Sierra", "given": "Olga", "sequence": "additional" }, { "affiliation": [], "family": "Molina Barcena", "given": "Verónica", "sequence": "additional" }, { "affiliation": [], "family": "Viejo Pinero", "given": "Nuria", "sequence": "additional" }, { "affiliation": [], "family": "Fernández Díaz", "given": "Carlos", "sequence": "additional" }, { "affiliation": [], "family": "Arroyo Burguillo", "given": "Purificación", "sequence": "additional" }, { "affiliation": [], "family": "Blanco Gallego", "given": "Ana María", "sequence": "additional" }, { "affiliation": [], "family": "Guirao Sánchez", "given": "Carmen", "sequence": "additional" }, { "affiliation": [], "family": "Montilla Bernabé", "given": "Aránzazu", "sequence": "additional" }, { "affiliation": [], "family": "Villanueva Morán", "given": "María del Pilar", "sequence": "additional" }, { "affiliation": [], "family": "Juárez Antón", "given": "Salvador", "sequence": "additional" }, { "affiliation": [], "family": "Fernández Rodríguez", "given": "Ángela", "sequence": "additional" }, { "affiliation": [], "family": "Somoza Calvo", "given": "María Ángeles", "sequence": "additional" }, { "affiliation": [], "family": "Cerrada", "given": "Ernesto Cerrada", "sequence": "additional" }, { "affiliation": [], "family": "Pérez Mañas", "given": "Gemma", "sequence": "additional" }, { "affiliation": [], "family": "Sánchez Calso", "given": "Antonio", "sequence": "additional" }, { "affiliation": [], "family": "Vallejo Somohano", "given": "Frida", "sequence": "additional" }, { "affiliation": [], "family": "Cauqui Díaz", "given": "Carmen", "sequence": "additional" }, { "affiliation": [], "family": "Viñas Fernández", "given": "Gloria", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-4716-3152", "affiliation": [], "authenticated-orcid": false, "family": "Molina París", "given": "Jesús", "sequence": "additional" }, { "affiliation": [], "family": "González Godoy", "given": "Marina", "sequence": "additional" }, { "affiliation": [], "family": "Lumbreras García", "given": "Gonzalo", "sequence": "additional" }, { "affiliation": [], "family": "Rosado Martín", "given": "Javier", "sequence": "additional" }, { "affiliation": [], "family": "Rodríguez Hernández", "given": "Aida", "sequence": "additional" }, { "affiliation": [], "family": "López Antúñez", "given": "Sara", "sequence": "additional" }, { "affiliation": [], "family": "Vázquez Perfecto", "given": "Gabriel", "sequence": "additional" }, { "affiliation": [], "family": "Marcello Andrés", "given": "María Concepción", "sequence": "additional" }, { "affiliation": [], "family": "Puente García", "given": "Nieves Marina", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-3882-6081", "affiliation": [], "authenticated-orcid": false, "family": "Gil", "given": "Carmen", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-2707-8110", "affiliation": [], "authenticated-orcid": false, "family": "Martínez", "given": "Ana", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-5853-2307", "affiliation": [], "authenticated-orcid": false, "family": "Soler López", "given": "Begoña", "sequence": "additional" } ], "container-title": "Journal of Clinical Medicine", "container-title-short": "JCM", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 12, 27 ] ], "date-time": "2022-12-27T07:53:11Z", "timestamp": 1672127591000 }, "deposited": { "date-parts": [ [ 2022, 12, 29 ] ], "date-time": "2022-12-29T09:11:50Z", "timestamp": 1672305110000 }, "funder": [ { "award": [ "PIE 201980E024" ], "name": "CSIC" }, { "award": [ "EU 2020/2094" ], "name": "European Commission: NextGeneration EU" } ], "indexed": { "date-parts": [ [ 2022, 12, 30 ] ], "date-time": "2022-12-30T06:09:20Z", "timestamp": 1672380560206 }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2022, 12, 24 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2023, 1 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 12, 24 ] ], "date-time": "2022-12-24T00:00:00Z", "timestamp": 1671840000000 } } ], "link": [ { "URL": "https://www.mdpi.com/2077-0383/12/1/142/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1968", "original-title": [], "page": "142", "prefix": "10.3390", "published": { "date-parts": [ [ 2022, 12, 24 ] ] }, "published-online": { "date-parts": [ [ 2022, 12, 24 ] ] }, "publisher": "MDPI AG", "reference": [ { "DOI": "10.2147/DDDT.S354841", "article-title": "A systematic Review of the global intervention for SARS-CoV-2 combating: From drugs repurposing to molnupiravir approval", "author": "Ashour", "doi-asserted-by": "crossref", "first-page": "685", "journal-title": "Drug Des. Dev. Ther.", "key": "ref_1", "volume": "16", "year": "2022" }, { "DOI": "10.1016/j.cell.2020.02.052", "article-title": "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", "author": "Hoffmann", "doi-asserted-by": "crossref", "first-page": "271", "journal-title": "Cell", "key": "ref_2", "volume": "181", "year": "2020" }, { "DOI": "10.1128/JVI.02232-10", "article-title": "Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response", "author": "Glowacka", "doi-asserted-by": "crossref", "first-page": "4122", "journal-title": "J. Virol.", "key": "ref_3", "volume": "85", "year": "2011" }, { "DOI": "10.1073/pnas.2002589117", "article-title": "Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells", "author": "Matsuyama", "doi-asserted-by": "crossref", "first-page": "7001", "journal-title": "Proc. Natl. Acad. Sci. USA", "key": "ref_4", "volume": "117", "year": "2020" }, { "DOI": "10.1016/j.biochi.2017.07.016", "article-title": "TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections", "author": "Shen", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Biochimie", "key": "ref_5", "volume": "142", "year": "2017" }, { "DOI": "10.1128/JVI.00002-21", "article-title": "SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in their requirements for receptor expression and proteolytic activation", "author": "Schlagowski", "doi-asserted-by": "crossref", "first-page": "e00002-21", "journal-title": "J. Virol.", "key": "ref_6", "volume": "95", "year": "2021" }, { "DOI": "10.1021/acs.jmedchem.0c00606", "article-title": "COVID-19: Drug Targets and Potential Treatments", "author": "Gil", "doi-asserted-by": "crossref", "first-page": "12359", "journal-title": "J. Med. Chem.", "key": "ref_7", "volume": "63", "year": "2020" }, { "DOI": "10.3390/ph14040332", "doi-asserted-by": "crossref", "key": "ref_8", "unstructured": "Ginex, T., Garaigorta, U., Ramírez, D., Castro, V., Nozal, V., Maestro, I., García-Cárceles, J., Campillo, N.E., Martinez, A., and Gastaminza, P. (2021). Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods. Pharmaceuticals, 14." }, { "DOI": "10.3389/fphar.2022.952192", "article-title": "Network pharmacology reveals mechanism of action of drugs to be repurposed for COVID-19", "author": "Barbosa", "doi-asserted-by": "crossref", "first-page": "952192", "journal-title": "Front. Pharmacol.", "key": "ref_9", "volume": "13", "year": "2022" }, { "DOI": "10.1007/s11739-020-02383-3", "article-title": "Potential new treatment strategies for COVID-19: Is there a role for bromhexine as add-on therapy?", "author": "Depfenhart", "doi-asserted-by": "crossref", "first-page": "801", "journal-title": "Intern. Emerg. Med.", "key": "ref_10", "volume": "15", "year": "2020" }, { "article-title": "The potential role of bromhexine in the management of COVID-19: Decipher and a real game-changer", "author": "Hussain", "first-page": "212", "journal-title": "Curr. Med. Drug Res.", "key": "ref_11", "volume": "5", "year": "2020" }, { "DOI": "10.1136/jim-2020-001747", "doi-asserted-by": "crossref", "key": "ref_12", "unstructured": "Tolouian, R., Mulla, Z.D., Jamaati, H., Babamahmoodi, A., Marjani, M., Eskandari, R., and Dastan, F. (2021). Effect of bromhexine in hospitalized patients with COVID-19. J. Investig. Med., 1–6." }, { "DOI": "10.34172/bi.2020.27", "article-title": "Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial", "author": "Ansarin", "doi-asserted-by": "crossref", "first-page": "209", "journal-title": "Bioimpacts", "key": "ref_13", "volume": "10", "year": "2020" }, { "DOI": "10.1155/2022/4693121", "article-title": "Bromhexine hydrochloride prophylaxis of COVID-19 for medical personnel: A randomized open-label study", "author": "Mikhaylov", "doi-asserted-by": "crossref", "first-page": "4693121", "journal-title": "Interdiscip. Perspect. Infect. Dis.", "key": "ref_14", "volume": "2022", "year": "2022" }, { "DOI": "10.1016/S0140-6736(20)30567-5", "article-title": "How will country-based mitigation measures influence the course of the COVID-19 epidemic?", "author": "Anderson", "doi-asserted-by": "crossref", "first-page": "931", "journal-title": "Lancet", "key": "ref_15", "volume": "395", "year": "2020" }, { "key": "ref_16", "unstructured": "Sociedad Española de Médicos de Atención Primaria (SEMERGEN) (2020). Protocolo de Actuación en Pacientes con COVID-19 Asistidos en Atención Primaria, Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Available online: https://www.semergen.es/files/docs/COVID-19/Documentos/ferrer-covid-19.pdf." }, { "key": "ref_17", "unstructured": "World Health Organization (2022, November 22). COVID-19 Clinical Management. This Document Is the Update of an Interim Guidance Originally Published under the Title “Clinical Management of COVID-19: Interim Guidance, 27 May 2020”. World Health Organization 2021. WHO Reference Number: WHO/2019-nCoV/clinical/2021.1. Available online: https://www.semergen.es/files/docs/COVID-19/Documentos/who-guide-covig192021.1-eng.pdf." }, { "DOI": "10.1007/s00228-020-02971-4", "article-title": "Re-recognizing bromhexine hydrochloride: Pharmaceutical properties and its possible role in treating pediatric COVID-19", "author": "Fu", "doi-asserted-by": "crossref", "first-page": "261", "journal-title": "Eur. J. Clin. Pharmacol.", "key": "ref_18", "volume": "77", "year": "2021" }, { "DOI": "10.1016/j.phrs.2020.104837", "article-title": "Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection", "author": "Maggio", "doi-asserted-by": "crossref", "first-page": "104837", "journal-title": "Pharmacol. Res.", "key": "ref_19", "volume": "157", "year": "2020" }, { "DOI": "10.1016/j.phrs.2020.104853", "article-title": "Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2", "author": "Habtemariam", "doi-asserted-by": "crossref", "first-page": "104853", "journal-title": "Pharmacol. Res.", "key": "ref_20", "volume": "157", "year": "2020" }, { "DOI": "10.36233/0507-4088-106", "article-title": "Bromhexine is a potential drug for COVID-19; From hypothesis to clinical trials", "author": "Bahadoram", "doi-asserted-by": "crossref", "first-page": "126", "journal-title": "Probl. Virol.", "key": "ref_21", "volume": "67", "year": "2022" }, { "key": "ref_22", "unstructured": "Ministerio de Sanidad (2022, November 22). Enfermedad por Coronavirus, COVID-19. Actualización 12 de Noviembre de 2020. Available online: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/ITCoronavirus/home.htm." }, { "DOI": "10.1097/MD.0000000000022114", "article-title": "Evaluating the efficacy and safety of bromhexine hydrochloride tablets in treating pediatric COVID-19: A protocol for meta-analysis and systematic review", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "e22114", "journal-title": "Medicine", "key": "ref_23", "volume": "99", "year": "2020" }, { "key": "ref_24", "unstructured": "(2022, November 22). Actualización de la Situación Epidemiológica de las Variantes SARS-CoV-2 en España. 26 de Septiembre de 2022. Ministerio de Sanidad. Available online: https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Actualizacion_variantes_20220926.pdf." } ], "reference-count": 24, "references-count": 24, "relation": {}, "resource": { "primary": { "URL": "https://www.mdpi.com/2077-0383/12/1/142" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Medicine" ], "subtitle": [], "title": "Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial", "type": "journal-article", "volume": "12" }